Last reviewed · How we verify

NCT06742164

Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock

Not yet recruiting NA Last updated 19 December 2024
What this trial tests

NA trial testing Ivabradine 5mg Tab in Heart Rhythm Disorder in 76 participants. Not yet recruiting.

Timeline
30 December 2024
Primary endpoint
30 June 2025
30 June 2025

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment76
Start date30 December 2024
Primary completion30 June 2025
Estimated completion30 June 2025

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

18 and older, any sex, with Heart Rhythm Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tachycardia is associated with excess mortality during septic shock. This may be related to the increase in cardiac metabolic demand, impaired cardiac diastolic function and less effect of administered exogenous catecholamines. In this study, we evaluate the effect of enteral Ivabradine on outcome of septic patients regarding need for vasopressor therapy, mechanical ventilation, renal replacement therapy, length of ICU stay and in-hospital mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ivabradine 5mg Tab

Trials testing the same drug.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742164.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing